InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,718.00
(
0.44%
)
Dow Jones
39,387.76
(
0.00%
)
Brent Oil
84.12
(
0.20%
)
Bitcoin
63,179.94
(
0.21%
)
Post# of 251778
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 56
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: DewDiligence post# 132527

Tuesday, 12/06/2011 3:40:14 PM

Tuesday, December 06, 2011 3:40:14 PM

Post# of 251778

Moreover, the fundamental design of this trial—using response rate as the primary endpoint in an open-label study—is hopelessly flawed.



Other than standard issues with open-label trials, why do you think the use of ORR as the primary in combination with open label is especially terrible?

Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up